Exelixis: Play the Two-Backbone Setup — Cabometyx Cash Engine Plus Zanzalintinib Growth
Exelixis combines a durable cash-generating franchise in Cabometyx with a newly approved, potentially multi-indication next-generation asset, zanzalintinib. The balance sheet and cash flow profile give a margin of safety; positive regulatory and clinical catalysts could expand valuation. This trade idea lays out an entry, stop, and target with a ra…